Parhelia Biosciences, the leader in sample preparation for tissue staining and spatial analysis – recently announced the successful completion of its Series A financing round. This milestone is a testament to the company’s ongoing focus on providing a single modular solution for spatial biology sample preparation.
The Series A funding round saw participation from Rabbit Run Partners, Thielsen Capital, and prominent industry angels. And this infusion of capital will accelerate the company’s growth, enabling Parhelia Biosciences to expand its robust menu of spatial offerings, scale its support and commercial efforts, and pursue strategic collaborations.
Parhelia Biosciences made significant strides since its inception, with placements across leading academic institutions and biopharma. And the Series A funding underscores market confidence in Parhelia Biosciences’ potential to transform and expand sample preparation for a wide menu of spatial protocols, including those already supported: Phenocycler (formerly CODEX) and Phenoptics (formerly Opal), immunohistochemistry (IHC), hematoxylin and eosin (H&E) staining, RNAScope, immunofluorescence (including CYCIF), and imaging mass cytometry (IMC).
KEY QUOTE:
“We’re incredibly grateful for the confidence our customers, partners and investors have shown in our vision and our team. This funding will enable us to accelerate the execution of our go-to-market strategy.”
— Dr. Nikolay Samuisk, Co-founder and CEO of Parhelia Biosciences
